Immune-Onc Therapeutics, a private, clinical-stage cancer immunotherapy company developing novel biotherapeutics targeting myeloid checkpoints announced the close of an additional $25 million through a Series B extension, for a total of $131 million in Series B financing.

This extension was led by existing investor Triwise Capital and with participation from new investors including Proxima Ventures, among others. In addition, the company has received continued strategic capital investments from The Leukemia & Lymphoma Society's Therapy Acceleration Program (LLS TAP) and Wuxi Biologics HealthCare Venture.